A Multi-Center, Open-Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-Sponsored Phase 1 Cancer Studies

Trial Profile

A Multi-Center, Open-Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-Sponsored Phase 1 Cancer Studies

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs RG 7112 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 05 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 31 Dec 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
    • 21 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top